VILOXAZINE

Details

Stereochemistry	RACEMIC
Molecular Formula	C13H19NO3
Molecular Weight	237.2954
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCOc1ccccc1OCC2CNCCO2

InChI

InChIKey=YWPHCCPCQOJSGZ-UHFFFAOYSA-N

InChI=1S/C13H19NO3/c1-2-15-12-5-3-4-6-13(12)17-10-11-9-14-7-8-16-11/h3-6,11,14H,2,7-10H2,1H3

HIDE SMILES / InChI

Molecular Formula	C13H19NO3
Molecular Weight	237.2954
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22454923 | https://www.ncbi.nlm.nih.gov/pubmed/324751 | http://bipolarnews.org/?tag=viloxazine | https://www.ncbi.nlm.nih.gov/pubmed/30924702

Viloxazine is an antidepressant drug was used to treat patients with depression. Viloxazine inhibits noradrenaline uptake. This drug was approved in some Europe countries, but not in the USA, but then it was discontinued because of competition from other drugs. In the frame of drug repositioning, Viloxazine participated in clinical trials for the treatment of attention deficit hyperactivity disorder. Phase II of trials was successfully passed.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Sodium-dependent noradrenaline transporter 17 Target ID: P23975 Gene ID: 6530.0 Gene Symbol: SLC6A2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/27230580	Inhibitor 3315
Sodium-dependent noradrenaline transporter 17 Target ID: P23975 Gene ID: 6530.0 Gene Symbol: SLC6A2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/27230580	Inhibitor 3315

PubMed

Title	Date	PubMed
[Comparative evaluation of the therapeutic efficacy of the antidepressants adepren, linamiphen and emovit].	1986	3716711
Intravenous antidepressant treatment: focus on citalopram.	2002 Jun	12192466
Tricyclic and related drugs for nocturnal enuresis in children.	2003	12917922
Contribution of sleep research to the development of new antidepressants.	2005	16416706
Development of a solid phase extraction for 13 'new' generation antidepressants and their active metabolites for gas chromatographic-mass spectrometric analysis.	2005 Dec 9	16314157
Internet-based search of randomised trials relevant to mental health originating in the Arab world.	2005 Jul 26	16045805
Enhancing central noradrenergic function in depression: is there still a place for a new antidepressant?	2005 Mar	18568121
Gastrointestinal bleeding and massive liver damage in neuroleptic malignant syndrome.	2005 Sep	18360563
A prognostic system applicable to patients with resectable liver metastasis from colorectal carcinoma staged by positron emission tomography with [18F]fluoro-2-deoxy-D-glucose: role of primary tumor variables.	2008 May	18471711
Adjustment Disorder: epidemiology, diagnosis and treatment.	2009 Jun 26	19558652
Determination of antidepressants in human postmortem blood, brain tissue, and hair using gas chromatography-mass spectrometry.	2009 Nov	18839201

Patents

Sample Use Guides

In Vivo Use Guide

100 mg

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Fri Jun 25 23:08:57 UTC 2021` Edited by `admin` on `Fri Jun 25 23:08:57 UTC 2021`
Record UNII	5I5Y2789ZF
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

VILOXAZINE

Official Name

English

VILOXAZINE [INN]

Common Name

English

VILOXAZINE [WHO-DD]

Common Name

English

VILOXAZINE [MI]

Common Name

English

MORPHOLINE, 2-((2-ETHOXYPHENOXY)METHYL)-

Systematic Name

English

(+/-)-2-(O-ETHOXYPHENOXYMETHYL)MORPHOLINE

Common Name

English

VILOXAZIN

Common Name

English

VILOXAZINE [VANDF]

Common Name

English

Classification Tree Code System Code

WHO-ATC

N06AX09